JP7296363B2 - 抗ctla-4抗体およびその使用 - Google Patents

抗ctla-4抗体およびその使用 Download PDF

Info

Publication number
JP7296363B2
JP7296363B2 JP2020503984A JP2020503984A JP7296363B2 JP 7296363 B2 JP7296363 B2 JP 7296363B2 JP 2020503984 A JP2020503984 A JP 2020503984A JP 2020503984 A JP2020503984 A JP 2020503984A JP 7296363 B2 JP7296363 B2 JP 7296363B2
Authority
JP
Japan
Prior art keywords
antibody
ctla
antigen
antibodies
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020503984A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020528750A5 (cg-RX-API-DMAC7.html
JP2020528750A (ja
Inventor
アイナー・ハーマン
エラ・イオッフェ
エレナ・ブローヴァ
ギャビン・サーストン
ウィリアム・オルソン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2020528750A publication Critical patent/JP2020528750A/ja
Publication of JP2020528750A5 publication Critical patent/JP2020528750A5/ja
Priority to JP2023095262A priority Critical patent/JP2023113893A/ja
Application granted granted Critical
Publication of JP7296363B2 publication Critical patent/JP7296363B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020503984A 2017-07-27 2018-07-26 抗ctla-4抗体およびその使用 Active JP7296363B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023095262A JP2023113893A (ja) 2017-07-27 2023-06-09 抗ctla-4抗体およびその使用

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762537753P 2017-07-27 2017-07-27
US62/537,753 2017-07-27
US201762588853P 2017-11-20 2017-11-20
US62/588,853 2017-11-20
US201862645284P 2018-03-20 2018-03-20
US62/645,284 2018-03-20
US201862685599P 2018-06-15 2018-06-15
US62/685,599 2018-06-15
PCT/US2018/043936 WO2019023482A1 (en) 2017-07-27 2018-07-26 ANTI-CTLA-4 ANTIBODIES AND USES THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023095262A Division JP2023113893A (ja) 2017-07-27 2023-06-09 抗ctla-4抗体およびその使用

Publications (3)

Publication Number Publication Date
JP2020528750A JP2020528750A (ja) 2020-10-01
JP2020528750A5 JP2020528750A5 (cg-RX-API-DMAC7.html) 2021-08-26
JP7296363B2 true JP7296363B2 (ja) 2023-06-22

Family

ID=63165545

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020503984A Active JP7296363B2 (ja) 2017-07-27 2018-07-26 抗ctla-4抗体およびその使用
JP2023095262A Pending JP2023113893A (ja) 2017-07-27 2023-06-09 抗ctla-4抗体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023095262A Pending JP2023113893A (ja) 2017-07-27 2023-06-09 抗ctla-4抗体およびその使用

Country Status (17)

Country Link
US (3) US10844137B2 (cg-RX-API-DMAC7.html)
EP (1) EP3658585A1 (cg-RX-API-DMAC7.html)
JP (2) JP7296363B2 (cg-RX-API-DMAC7.html)
KR (1) KR102710122B1 (cg-RX-API-DMAC7.html)
CN (1) CN111133004B (cg-RX-API-DMAC7.html)
AU (1) AU2018307675B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020001266A2 (cg-RX-API-DMAC7.html)
CL (1) CL2020000216A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020000438A2 (cg-RX-API-DMAC7.html)
IL (1) IL271882B2 (cg-RX-API-DMAC7.html)
MA (1) MA49687A (cg-RX-API-DMAC7.html)
MY (1) MY202870A (cg-RX-API-DMAC7.html)
PH (1) PH12020500078A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202000366WA (cg-RX-API-DMAC7.html)
TW (1) TWI799432B (cg-RX-API-DMAC7.html)
WO (1) WO2019023482A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202000113B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023113893A (ja) * 2017-07-27 2023-08-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ctla-4抗体およびその使用

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL307242B1 (en) 2016-12-07 2026-07-01 Agenus Inc Anti-CTLA-4 antibodies and methods of using them
TWI850282B (zh) 2018-11-27 2024-08-01 香港商弘年發展有限公司 用於治療癌症之質體建構體和使用方法
WO2020127377A1 (en) 2018-12-21 2020-06-25 Ose Immunotherapeutics Bifunctional anti-pd-1/il-7 molecule
CN114008071B (zh) 2018-12-27 2025-01-21 吉加根公司 抗ctla-4结合蛋白及其使用方法
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
MA55204A (fr) * 2019-03-06 2022-01-12 Regeneron Pharma Inhibiteurs de la voie il-4/il-13 pour une efficacité améliorée dans le traitement du cancer
MA55316A (fr) 2019-03-13 2022-01-19 Merck Sharp & Dohme Polythérapies anticancéreuses comprenant des agents de blocage de ctla-4 et pd-1
EP4054723A1 (en) 2019-11-08 2022-09-14 Bristol-Myers Squibb Company Lag-3 antagonist therapy for melanoma
TW202136287A (zh) 2019-12-17 2021-10-01 法商Ose免疫治療公司 包含il-7變體之雙官能分子
JP2023510132A (ja) * 2019-12-20 2023-03-13 メルク・シャープ・アンド・ドーム・エルエルシー Pd-1アンタゴニスト、ilt4アンタゴニストおよび化学療法剤の組合せを使用して癌を治療する方法
EP4139440B1 (en) 2020-04-22 2026-08-19 Iovance Biotherapeutics, Inc. Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
TW202216771A (zh) * 2020-06-26 2022-05-01 德商拜耳廠股份有限公司 用於治療應用之ccr8抗體
US20230265192A1 (en) * 2020-07-02 2023-08-24 Gigagen, Inc. Anti-ctla-4 binding proteins and methods of use thereof
CA3185091A1 (en) * 2020-07-08 2022-01-13 Yuan Cheng Stabilized formulations containing anti-ctla-4 antibodies
CA3195019A1 (en) 2020-10-06 2022-04-14 Maria Fardis Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
WO2022112198A1 (en) 2020-11-24 2022-06-02 Worldwide Innovative Network Method to select the optimal immune checkpoint therapies
WO2022127882A1 (zh) * 2020-12-17 2022-06-23 南京蓬勃生物科技有限公司 筛选靶向CD47-SIRPα免疫检查点的候选药物的方法和试剂盒
JP2023554395A (ja) 2020-12-17 2023-12-27 アイオバンス バイオセラピューティクス,インコーポレイテッド Ctla-4及びpd-1阻害剤と併用した腫瘍浸潤リンパ球療法による治療
EP4314253A2 (en) 2021-03-25 2024-02-07 Iovance Biotherapeutics, Inc. Methods and compositions for t-cell coculture potency assays and use with cell therapy products
EP4320156A1 (en) 2021-04-09 2024-02-14 Ose Immunotherapeutics Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
MX2023011964A (es) 2021-04-09 2024-01-08 Ose Immunotherapeutics Nuevo andamio para moléculas bifuncionales con propiedades mejoradas.
WO2022245820A1 (en) 2021-05-17 2022-11-24 Emory University Vasoactive intestinal peptide (vip) receptor antagonists
MX2024004429A (es) * 2021-10-29 2024-05-06 Oncoc4 Inc Regimenes de dosificacion del anticuerpo anti-ctla-4.
MX2024006187A (es) 2021-11-24 2024-08-14 Regeneron Pharma Métodos para tratar el cáncer con anticuerpos biespecíficos anti-cd3 x muc16 y anticuerpos anti-ctla-4.
CN118541390A (zh) * 2022-01-30 2024-08-23 百奥赛图(北京)医药科技股份有限公司 抗ctla4/ox40双特异性抗体及其用途
EP4507704A1 (en) 2022-04-15 2025-02-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment
WO2024003360A1 (en) 2022-07-01 2024-01-04 Institut Curie Biomarkers and uses thereof for the treatment of neuroblastoma
EP4565610A1 (en) 2022-08-02 2025-06-11 Ose Immunotherapeutics Multifunctional molecule directed against cd28
WO2024112571A2 (en) 2022-11-21 2024-05-30 Iovance Biotherapeutics, Inc. Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom
WO2024200820A1 (en) 2023-03-30 2024-10-03 Ose Immunotherapeutics Method of synthesis of targeted lipid nanoparticle and uses thereof
JP2026512425A (ja) 2023-03-30 2026-04-16 オーエスイー・イミュノセラピューティクス 免疫細胞増強分子の発現のための活性化免疫細胞に標的化された脂質ベースのナノ粒子及びその使用
EP4727974A1 (en) * 2023-06-16 2026-04-22 Genor Biopharma Co., Ltd. Anti-ccr8 antibody and anti-ccr8/ctla4 bispecific antibody
WO2025140478A1 (zh) * 2023-12-29 2025-07-03 百奥泰生物制药股份有限公司 抗pd-l1/cd47双特异抗体在联合用药中的应用
WO2025242835A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of cancer
WO2026068705A1 (en) 2024-09-26 2026-04-02 Ose Immunotherapeutics Lipid-based nanoparticles comprising non-glycosylated fc domains and uses thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002537226A (ja) 1998-12-23 2002-11-05 ファイザー インコーポレーテッド Ctla−4に対するヒトモノクローナル抗体
WO2009100140A1 (en) 2008-02-04 2009-08-13 Medarex, Inc. Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof
JP2014512809A (ja) 2011-03-09 2014-05-29 アンチトープ・リミテッド ヒト化抗ctla4抗体
WO2016130986A1 (en) 2015-02-13 2016-08-18 Sorrento Therapeutics, Inc. Antibody therapeutics that bind ctla4
WO2016196237A1 (en) 2015-05-29 2016-12-08 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
WO2017084078A1 (en) 2015-11-19 2017-05-26 Zeling Cai Ctla-4 antibodies and uses thereof
WO2018107178A1 (en) 2016-12-09 2018-06-14 Regeneron Pharmaceuticals, Inc. Systems and methods for sequencing t cell receptors and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
TWI680138B (zh) * 2014-01-23 2019-12-21 美商再生元醫藥公司 抗pd-l1之人類抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對pd-1的人類抗體
AU2015229591B2 (en) * 2014-03-11 2020-10-22 Regeneron Pharmaceuticals, Inc. Anti-EGFRvlll antibodies and uses thereof
TWI754319B (zh) * 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
TWI799432B (zh) * 2017-07-27 2023-04-21 美商再生元醫藥公司 抗ctla-4抗體及其用途

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002537226A (ja) 1998-12-23 2002-11-05 ファイザー インコーポレーテッド Ctla−4に対するヒトモノクローナル抗体
WO2009100140A1 (en) 2008-02-04 2009-08-13 Medarex, Inc. Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof
JP2014512809A (ja) 2011-03-09 2014-05-29 アンチトープ・リミテッド ヒト化抗ctla4抗体
WO2016130986A1 (en) 2015-02-13 2016-08-18 Sorrento Therapeutics, Inc. Antibody therapeutics that bind ctla4
WO2016196237A1 (en) 2015-05-29 2016-12-08 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
WO2017084078A1 (en) 2015-11-19 2017-05-26 Zeling Cai Ctla-4 antibodies and uses thereof
WO2018107178A1 (en) 2016-12-09 2018-06-14 Regeneron Pharmaceuticals, Inc. Systems and methods for sequencing t cell receptors and uses thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Burova, E. et al.,Abstract 3824: Antitumor activity of REGN4659, a fully human anti-CTLA-4 monoclonal antibody, against MC38.Ova tumors grown in immunocompetent humanh CTLA-4 knoc-in mice,Cancer Res,2018年07月01日,78(13_Supplement)
Funt, S. A. et al.,CTLA-4 antibodies: new directions, new combinations,Oncology,2014年,28(3),1-14
Hodi, F. S. et al,Improved survival with ipilimumab in patients with metastatic melanoma,N Engl J Med.,2010年,363;8,711-723
Kirkwood, J. M. et al.,Phase II trial of tremelimumab (CP-675, 206) in patients with advanced refractory or relapsed melanoma,Clin Cancer Res.,2010年,16(3),1042-1048
Larkin, J. et al.,Combined nivolmab and ipilimumab or monotherapy in untreated melanoma,N Engl J Med.,2015年,373;1,23-34
Ribas, A. et al.,Tremelimumab (CP-675, 206), a cytotoxic T lymphocyte-associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer,The Oncologist,2007年,12,873-883

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023113893A (ja) * 2017-07-27 2023-08-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ctla-4抗体およびその使用

Also Published As

Publication number Publication date
IL271882B2 (en) 2025-06-01
US20250122307A1 (en) 2025-04-17
EP3658585A1 (en) 2020-06-03
CA3070790A1 (en) 2019-01-31
CL2020000216A1 (es) 2020-07-10
AU2018307675B2 (en) 2024-08-01
CO2020000438A2 (es) 2020-01-31
CN111133004A (zh) 2020-05-08
US20210040232A1 (en) 2021-02-11
ZA202000113B (en) 2021-07-28
IL271882A (en) 2020-02-27
KR102710122B1 (ko) 2024-09-27
US10844137B2 (en) 2020-11-24
PH12020500078A1 (en) 2020-11-09
MY202870A (en) 2024-05-27
JP2020528750A (ja) 2020-10-01
SG11202000366WA (en) 2020-02-27
WO2019023482A1 (en) 2019-01-31
US20190048096A1 (en) 2019-02-14
BR112020001266A2 (pt) 2020-07-28
TWI799432B (zh) 2023-04-21
AU2018307675A1 (en) 2020-02-20
US12024570B2 (en) 2024-07-02
CN111133004B (zh) 2023-12-01
KR20200032189A (ko) 2020-03-25
IL271882B1 (en) 2025-02-01
TW201920267A (zh) 2019-06-01
MA49687A (fr) 2020-06-03
JP2023113893A (ja) 2023-08-16

Similar Documents

Publication Publication Date Title
US12024570B2 (en) Anti-CTLA-4 antibodies and uses thereof
JP7562606B2 (ja) Pd-1に対するヒト抗体
US20240166740A1 (en) Anti-lag3 antibodies and uses thereof
JP2024164199A (ja) Psmaおよびcd3に結合する二重特異性抗原結合分子の4-1bb共刺激と組み合わせての使用
CA3070790C (en) Anti-ctla-4 antibodies and uses thereof
EA042000B1 (ru) Анти-ctla-4 антитела и их применение

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210715

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210715

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220517

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220831

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230308

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230516

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230612

R150 Certificate of patent or registration of utility model

Ref document number: 7296363

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150